Aitor Nogales

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3556507/publications.pdf

Version: 2024-02-01

102 papers	3,030 citations	159585 30 h-index	223800 46 g-index
108 all docs	108 docs citations	108 times ranked	3308 citing authors

#	Article	IF	Citations
1	Construction of a Severe Acute Respiratory Syndrome Coronavirus Infectious cDNA Clone and a Replicon To Study Coronavirus RNA Synthesis. Journal of Virology, 2006, 80, 10900-10906.	3.4	198
2	Influenza A Virus Attenuation by Codon Deoptimization of the NS Gene for Vaccine Development. Journal of Virology, 2014, 88, 10525-10540.	3.4	133
3	Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response. Journal of Virology, 2016, 90, 5399-5414.	3.4	110
4	A Guide to Signaling Pathways Connecting Protein-Glycan Interaction with the Emerging Versatile Effector Functionality of Mammalian Lectins. Trends in Glycoscience and Glycotechnology, 2006, 18, 1-37.	0.1	103
5	Reverse Genetics Approaches for the Development of Influenza Vaccines. International Journal of Molecular Sciences, 2017, 18, 20.	4.1	90
6	Interferon-Induced Protein 44 Interacts with Cellular FK506-Binding Protein 5, Negatively Regulates Host Antiviral Responses, and Supports Virus Replication. MBio, 2019, 10, .	4.1	88
7	Influenza A and B Virus Intertypic Reassortment through Compatible Viral Packaging Signals. Journal of Virology, 2014, 88, 10778-10791.	3.4	83
8	Replication-competent influenza A viruses expressing a red fluorescent protein. Virology, 2015, 476, 206-216.	2.4	70
9	Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins. Viruses, 2018, 10, 708.	3.3	66
10	Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization. Journal of Virology, 2015, 89, 3523-3533.	3.4	65
11	Host cell proteins interacting with the 3â€² end of TGEV coronavirus genome influence virus replication. Virology, 2009, 391, 304-314.	2.4	63
12	Replication-Competent Influenza A Viruses Expressing Reporter Genes. Viruses, 2016, 8, 179.	3.3	57
13	Functional Evolution of Influenza Virus NS1 Protein in Currently Circulating Human 2009 Pandemic H1N1 Viruses. Journal of Virology, 2017, 91, .	3.4	51
14	Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus. Journal of Virology, 2019, 93, .	3.4	50
15	A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Scientific Reports, 2018, 8, 4374.	3.3	49
16	Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus. Journal of Virology, 2017, 91, .	3.4	48
17	Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein. Virology, 2017, 501, 35-46.	2.4	48
18	Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses. Journal of Virology, 2020, 94, .	3.4	48

#	Article	IF	Citations
19	Antigenicity of the 2015â€“2016 seasonal H1N1 human influenza virus HA and NA proteins. PLoS ONE, 2017, 12, e0188267.	2.5	46
20	Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. Journal of Virology, 2016, 90, 6291-6302.	3.4	44
21	Novel Approaches for The Development of Live Attenuated Influenza Vaccines. Viruses, 2019, 11, 190.	3.3	44
22	Development and applications of single-cycle infectious influenza A virus (sciIAV). Virus Research, 2016, 216, 26-40.	2.2	43
23	NS1 Protein Amino Acid Changes D189N and V194I Affect Interferon Responses, Thermosensitivity, and Virulence of Circulating H3N2 Human Influenza A Viruses. Journal of Virology, 2017, 91, .	3.4	43
24	A Novel Fluorescent and Bioluminescent Bireporter Influenza A Virus To Evaluate Viral Infections. Journal of Virology, 2019, 93, .	3.4	43
25	Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans. Journal of Virology, 2018, 92, .	3.4	42
26	Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine. Journal of Virology, 2015, 89, 3421-3426.	3.4	37
27	Replication-competent fluorescent-expressing influenza B virus. Virus Research, 2016, 213, 69-81.	2.2	37
28	Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine. Viruses, 2018, 10, 560.	3.3	36
29	NS1 Protein Mutation I64T Affects Interferon Responses and Virulence of Circulating H3N2 Human Influenza A Viruses. Journal of Virology, 2016, 90, 9693-9711.	3.4	34
30	Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication. Nucleic Acid Therapeutics, 2016, 26, 277-285.	3.6	34
31	A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. MBio, 2020, 11, .	4.1	34
32	Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines. Future Virology, 2015, 10, 715-730.	1.8	33
33	Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L505-L513.	2.9	33
34	An Alanine-to-Valine Substitution in the Residue 175 of Zika Virus NS2A Protein Affects Viral RNA Synthesis and Attenuates the Virus In Vivo. Viruses, 2018, 10, 547.	3.3	32
35	Replication-Competent Influenza A and B Viruses Expressing a Fluorescent Dynamic Timer Protein for In Vitro and In Vivo Studies. PLoS ONE, 2016, 11, e0147723.	2.5	32
36	Mammalian Adaptation of an Avian Influenza A Virus Involves Stepwise Changes in NS1. Journal of Virology, 2018, 92, .	3.4	31

#	Article	IF	Citations
37	The adaptor Grb7 is a novel calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7. Oncogene, 2005, 24, 4206-4219.	5.9	29
38	Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo. Scientific Reports, 2017, 7, 10857.	3.3	29
39	Characterizing Emerging Canine H3 Influenza Viruses. PLoS Pathogens, 2020, 16, e1008409.	4.7	29
40	Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology, 2017, 500, 1-10.	2.4	28
41	Host Single Nucleotide Polymorphisms Modulating Influenza A Virus Disease in Humans. Pathogens, 2019, 8, 168.	2.8	28
42	A live-attenuated influenza vaccine for H3N2 canine influenza virus. Virology, 2017, 504, 96-106.	2.4	27
43	Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo. Frontiers in Microbiology, 2019, 10, 2862.	3.5	27
44	Influenza A Virus Studies in a Mouse Model of Infection. Journal of Visualized Experiments, 2017, , .	0.3	26
45	Development of a novel equine influenza virus live-attenuated vaccine. Virology, 2018, 516, 76-85.	2.4	26
46	Mutations Designed by Ensemble Defect to Misfold Conserved RNA Structures of Influenza A Segments 7 and 8 Affect Splicing and Attenuate Viral Replication in Cell Culture. PLoS ONE, 2016, 11, e0156906.	2.5	26
47	The K186E Amino Acid Substitution in the Canine Influenza Virus H3N8 NS1 Protein Restores Its Ability To Inhibit Host Gene Expression. Journal of Virology, 2017, 91, .	3.4	25
48	Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells. MBio, 2019, 10, .	4.1	24
49	Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor. Viruses, 2019, 11, 35.	3.3	24
50	Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA). Vaccine, 2015, 33, 3562-3570.	3.8	23
51	Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine. Journal of Virology, 2017, 91, .	3.4	23
52	Reverse Genetic Approaches for the Generation of Recombinant Zika Virus. Viruses, 2018, 10, 597.	3.3	23
53	Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice. PLoS ONE, 2018, 13, e0193680.	2.5	23
54	A natural polymorphism in Zika virus NS2A protein responsible of virulence in mice. Scientific Reports, 2019, 9, 19968.	3.3	23

#	Article	IF	Citations
55	Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid. Frontiers in Microbiology, 2019, 10, 718.	3.5	22
56	A protective bivalent vaccine against Rift Valley fever and bluetongue. Npj Vaccines, 2020, 5, 70.	6.0	22
57	Reverse Genetics of Influenza B Viruses. Methods in Molecular Biology, 2017, 1602, 205-238.	0.9	21
58	Comparative Study of the Temperature Sensitive, Cold Adapted and Attenuated Mutations Present in the Master Donor Viruses of the Two Commercial Human Live Attenuated Influenza Vaccines. Viruses, 2019, 11, 928.	3.3	21
59	Rescue of Recombinant Zika Virus from a Bacterial Artificial Chromosome cDNA Clone. Journal of Visualized Experiments, 2019, , .	0.3	20
60	Engineering Infectious cDNAs of Coronavirus as Bacterial Artificial Chromosomes. Methods in Molecular Biology, 2015, 1282, 135-152.	0.9	20
61	Identification of a Gamma Interferon-Activated Inhibitor of Translation-Like RNA Motif at the 3â€² End of the Transmissible Gastroenteritis Coronavirus Genome Modulating Innate Immune Response. MBio, 2015, 6, e00105.	4.1	19
62	Crowd on a Chip: Label-Free Human Monoclonal Antibody Arrays for Serotyping Influenza. Analytical Chemistry, 2018, 90, 9583-9590.	6.5	19
63	Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine. Pathogens, 2020, 9, 86.	2.8	18
64	A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus. Journal of Virology, 2020, 94, .	3.4	18
65	Identification of Inhibitors of ZIKV Replication. Viruses, 2020, 12, 1041.	3.3	17
66	Identification of Amino Acid Residues Responsible for Inhibition of Host Gene Expression by Influenza A H9N2 NS1 Targeting of CPSF30. Frontiers in Microbiology, 2018, 9, 2546.	3.5	15
67	Influenza Viruses in Mice: Deep Sequencing Analysis of Serial Passage and Effects of Sialic Acid Structural Variation. Journal of Virology, 2019, 93, .	3.4	15
68	Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus. Vaccines, 2020, 8, 346.	4.4	15
69	A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses. Vaccine, 2017, 35, 4374-4381.	3.8	14
70	A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection. Journal of Visualized Experiments, 2019, , .	0.3	14
71	In vivo rescue of recombinant Zika virus from an infectious cDNA clone and its implications in vaccine development. Scientific Reports, 2020, 10, 512.	3.3	14
72	Viral Vector Vaccines against Bluetongue Virus. Microorganisms, 2021, 9, 42.	3.6	14

#	Article	IF	Citations
73	Transmissible Gastroenteritis Coronavirus RNA-Dependent RNA Polymerase and Nonstructural Proteins 2, 3, and 8 Are Incorporated into Viral Particles. Journal of Virology, 2012, 86, 1261-1266.	3.4	13
74	Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development. Microbiology Spectrum, 2022, 10, e0027222.	3.0	12
75	Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. Vaccine, 2020, 38, 882-889.	3.8	11
76	A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus. Viruses, 2019, 11, 933.	3.3	10
77	Inhibition of Orbivirus Replication by Aurintricarboxylic Acid. International Journal of Molecular Sciences, 2020, 21, 7294.	4.1	10
78	Natural Selection of H5N1 Avian Influenza A Viruses with Increased PA-X and NS1 Shutoff Activity. Viruses, 2021, 13, 1760.	3.3	10
79	Bi-Reporter Vaccinia Virus for Tracking Viral Infections In Vitro and In Vivo. Microbiology Spectrum, 2021, 9, e0160121.	3.0	10
80	Immunity to Influenza Infection in Humans. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038729.	6.2	8
81	Immunogenic characterization and epitope mapping of transmissible gastroenteritis virus RNA dependent RNA polymerase. Journal of Virological Methods, 2011, 175, 7-13.	2.1	7
82	AGL2017-82570-RReverse genetics approaches for the development of new vaccines against influenza A virus infections. Current Opinion in Virology, 2020, 44, 26-34.	5.4	7
83	A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs. Viruses, 2020, 12, 167.	3.3	7
84	Identification of Amino Acid Residues Required for Inhibition of Host Gene Expression by Influenza Virus A/Viet Nam/1203/2004 H5N1 PA-X. Journal of Virology, 2022, 96, JVI0040821.	3.4	7
85	Influenza Virus and Vaccination. Pathogens, 2020, 9, 220.	2.8	5
86	The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 Bluetongue Virus Challenge. Journal of Virology, 2022, 96, JVI0161421.	3.4	5
87	Oxygen-dependent changes in lung development do not affect epithelial infection with influenza A virus. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L940-L949.	2.9	4
88	Aryl and Arylalkyl Substituted 3â€Hydroxypyridinâ€2(1 H)â€ones: Synthesis and Evaluation as Inhibitors of Influenzaâ€…A Endonuclease. ChemMedChem, 2019, 14, 1204-1223.	3.2	4
89	Amino Acid Residues Involved in Inhibition of Host Gene Expression by Influenza A/Brevig Mission/1/1918 PA-X. Microorganisms, 2021, 9, 1109.	3.6	4
90	Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine. Microbiology Spectrum, 2022, 10, e0007822.	3.0	4

#	Article	IF	Citations
91	Dung biomass smoke exposure impairs resolution of inflammatory responses to influenza infection. Toxicology and Applied Pharmacology, 2022, 450, 116160.	2.8	4
92	Replication-Competent Î”NS1 Influenza A Viruses Expressing Reporter Genes. Viruses, 2021, 13, 698.	3.3	2
93	A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines. Viruses, 2021, 13, 1278.	3.3	2
94	Generation, Characterization, and Applications of Influenza A Reporter Viruses. Methods in Molecular Biology, 2022, , 249-268.	0.9	2
95	Editorial overview: Virus reverse genetics approaches for the development of preventive and therapeutic vaccines. Current Opinion in Virology, 2020, 44, iii-iv.	5.4	1
96	Generation and Characterization of Single-Cycle Infectious A (sciCIV) and Its Use as Vaccine Platform. Methods in Molecular Biology, 2022, 2465, 227-255.	0.9	0
97	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
98	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
99	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
100	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
101	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0
102	Characterizing Emerging Canine H3 Influenza Viruses. , 2020, 16, e1008409.		0